Avalyn to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced that management will participate in the Jefferies Global Healthcare Conference.

About Avalyn PharmaAvalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases including pulmonary fibrosis and other interstitial lung diseases (ILD). Pulmonary fibrosis is characterized by scarring, decline in lung function, reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies. For more information, please visit avalynpharma.com and follow us on LinkedIn.

Contacts:Monique AllaireTHRUST Strategic Communications[email protected]

You May Also Be Interested In

• adapfin to Build a Banking Product Live in Under Seven Minutes at Finovate Fall 2026
• Driving California's Energy Future: California Resources Corporation Releases 2025 Sustainability Update
• Subscribr Launches AI Platform to Ideate, Script and Edit a Month of YouTube Videos in a Day